. The Company’s pipeline includes four scientific-stage therapies. Its most Innovative drug candidate is ROS1 inhibitor taletrectinib for treating lung most cancers. Nuvation is completing two phase 2 pivotal experiments on taletrectinib. IV Percentile: The percentage of days with IV closing below the current IV value over the prior https://financefeeds.com/ark-invest-scoops-up-over-13m-in-copyright-shares-amid-market-slump/